Argus upgraded Integra from Hold to Buy and set a new price target of $25.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2026 | $25.00 | Hold → Buy | Argus |
| 5/28/2026 | $16.00 | Sell → Neutral | Citigroup |
| 4/15/2026 | Buy → Hold | Argus | |
| 3/31/2025 | Hold → Buy | Argus | |
| 12/2/2024 | $25.00 → $20.00 | Underweight | Morgan Stanley |
| 10/7/2024 | Sell → Neutral | BTIG Research | |
| 7/30/2024 | $22.00 | Neutral → Sell | BTIG Research |
| 7/30/2024 | $30.00 → $23.00 | Neutral → Sell | Citigroup |
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (NASDAQ:IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy. Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Ki
Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a problem to be solved. When skin, bone, or soft tissue is destroyed by injury, surgery, disease, or age, the standard of care has largely been about coverage and replacement — grafts, implants, fillers,
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and ti
Argus upgraded Integra from Hold to Buy and set a new price target of $25.00
Citigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00
Argus downgraded Integra from Buy to Hold
SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (NASDAQ:IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy. Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Ki
MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings
Stuart Essig Appointed as Integra's Next President and Chief Executive OfficerMichael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra's Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities. The Company also announced that Michael McBreen, currently executive vice president, president, Codman S
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the con